1. Home
  2. TBB vs HUMAW Comparison

TBB vs HUMAW Comparison

Compare TBB & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AT&T Inc.

TBB

AT&T Inc.

HOLD

Current Price

$22.78

Market Cap

0.0

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

N/A

Current Price

$0.10

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TBB
HUMAW
Founded
N/A
2004
Country
United States
United States
Employees
140990
220
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
TBB
HUMAW
Price
$22.78
$0.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
14.2K
Earning Date
N/A
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.18
52 Week High
N/A
$1.34

Technical Indicators

Market Signals
Indicator
TBB
HUMAW
Relative Strength Index (RSI) 65.27 48.90
Support Level $22.50 $0.10
Resistance Level $22.68 $0.15
Average True Range (ATR) 0.14 0.03
MACD 0.05 0.01
Stochastic Oscillator 93.85 60.18

Price Performance

Historical Comparison
TBB
HUMAW

About TBB AT&T Inc.

The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 12% of revenue, primarily consist of broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 24 million customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: